James E Tisdale1, Heather A Jaynes2, Joanna R Kingery2, Brian R Overholser2, Noha A Mourad2, Tate N Trujillo2, Richard J Kovacs2. 1. From the Department of Pharmacy Practice, College of Pharmacy, Purdue University, Indianapolis, IN (J.E.T., H.A.J., B.R.O., N.A.M.); Department of Medicine, School of Medicine, Indiana University, Indianapolis (J.E.T., B.R.O., R.J.K.); Department of Pharmacy, Indiana University Health Methodist Hospital, Indianapolis (J.R.K., T.N.T.). jtisdale@purdue.edu. 2. From the Department of Pharmacy Practice, College of Pharmacy, Purdue University, Indianapolis, IN (J.E.T., H.A.J., B.R.O., N.A.M.); Department of Medicine, School of Medicine, Indiana University, Indianapolis (J.E.T., B.R.O., R.J.K.); Department of Pharmacy, Indiana University Health Methodist Hospital, Indianapolis (J.R.K., T.N.T.).
Abstract
BACKGROUND: We evaluated the effectiveness of a computer clinical decision support system (CDSS) for reducing the risk of QT interval prolongation in hospitalized patients. METHODS AND RESULTS: We evaluated 2400 patients admitted to cardiac care units at an urban academic medical center. A CDSS incorporating a validated risk score for QTc prolongation was developed and implemented using information extracted from patients' electronic medical records. When a drug associated with torsades de pointes was prescribed to a patient at moderate or high risk for QTc interval prolongation, a computer alert appeared on the screen to the pharmacist entering the order, who could then consult the prescriber on alternative therapies and implement more intensive monitoring. QTc interval prolongation was defined as QTc interval >500 ms or increase in QTc of ≥60 ms from baseline; for patients who presented with QTc >500 ms, QTc prolongation was defined solely as increase in QTc ≥60 ms from baseline. End points were assessed before (n=1200) and after (n=1200) implementation of the CDSS. CDSS implementation was independently associated with a reduced risk of QTc prolongation (adjusted odds ratio, 0.65; 95% confidence interval, 0.56-0.89; P<0.0001). Furthermore, CDSS implementation reduced the prescribing of noncardiac medications known to cause torsades de pointes, including fluoroquinolones and intravenous haloperidol (adjusted odds ratio, 0.79; 95% confidence interval, 0.63-0.91; P=0.03). CONCLUSIONS: A computer CDSS incorporating a validated risk score for QTc prolongation influences the prescribing of QT-prolonging drugs and reduces the risk of QTc interval prolongation in hospitalized patients with torsades de pointes risk factors.
BACKGROUND: We evaluated the effectiveness of a computer clinical decision support system (CDSS) for reducing the risk of QT interval prolongation in hospitalized patients. METHODS AND RESULTS: We evaluated 2400 patients admitted to cardiac care units at an urban academic medical center. A CDSS incorporating a validated risk score for QTc prolongation was developed and implemented using information extracted from patients' electronic medical records. When a drug associated with torsades de pointes was prescribed to a patient at moderate or high risk for QTc interval prolongation, a computer alert appeared on the screen to the pharmacist entering the order, who could then consult the prescriber on alternative therapies and implement more intensive monitoring. QTc interval prolongation was defined as QTc interval >500 ms or increase in QTc of ≥60 ms from baseline; for patients who presented with QTc >500 ms, QTc prolongation was defined solely as increase in QTc ≥60 ms from baseline. End points were assessed before (n=1200) and after (n=1200) implementation of the CDSS. CDSS implementation was independently associated with a reduced risk of QTc prolongation (adjusted odds ratio, 0.65; 95% confidence interval, 0.56-0.89; P<0.0001). Furthermore, CDSS implementation reduced the prescribing of noncardiac medications known to cause torsades de pointes, including fluoroquinolones and intravenous haloperidol (adjusted odds ratio, 0.79; 95% confidence interval, 0.63-0.91; P=0.03). CONCLUSIONS: A computer CDSS incorporating a validated risk score for QTc prolongation influences the prescribing of QT-prolonging drugs and reduces the risk of QTc interval prolongation in hospitalized patients with torsades de pointes risk factors.
Authors: David Pickham; Eric Helfenbein; Julie A Shinn; Garrett Chan; Marjorie Funk; Ann Weinacker; Jia-Ni Liu; Barbara J Drew Journal: Crit Care Med Date: 2012-02 Impact factor: 7.598
Authors: Thomas Isaac; Joel S Weissman; Roger B Davis; Michael Massagli; Adrienne Cyrulik; Daniel Z Sands; Saul N Weingart Journal: Arch Intern Med Date: 2009-02-09
Authors: Emmanuel Eschmann; Patrick E Beeler; Vladimir Kaplan; Markus Schneemann; Gregor Zünd; Jürg Blaser Journal: Stud Health Technol Inform Date: 2012
Authors: James E Tisdale; Heather A Wroblewski; Brian R Overholser; Joanna R Kingery; Tate N Trujillo; Richard J Kovacs Journal: Drug Saf Date: 2012-06-01 Impact factor: 5.606
Authors: Andrew J Sauer; Arthur J Moss; Scott McNitt; Derick R Peterson; Wojciech Zareba; Jennifer L Robinson; Ming Qi; Ilan Goldenberg; Jenny B Hobbs; Michael J Ackerman; Jesaia Benhorin; W Jackson Hall; Elizabeth S Kaufman; Emanuela H Locati; Carlo Napolitano; Silvia G Priori; Peter J Schwartz; Jeffrey A Towbin; G Michael Vincent; Li Zhang Journal: J Am Coll Cardiol Date: 2007-01-04 Impact factor: 24.094
Authors: James E Tisdale; Heather A Jaynes; Joanna R Kingery; Noha A Mourad; Tate N Trujillo; Brian R Overholser; Richard J Kovacs Journal: Circ Cardiovasc Qual Outcomes Date: 2013-05-28
Authors: A J Moss; P J Schwartz; R S Crampton; D Tzivoni; E H Locati; J MacCluer; W J Hall; L Weitkamp; G M Vincent; A Garson Journal: Circulation Date: 1991-09 Impact factor: 29.690
Authors: Raymond L Woosley; Klaus Romero; Craig W Heise; Tyler Gallo; Jared Tate; Raymond David Woosley; Sophie Ward Journal: Drug Saf Date: 2017-06 Impact factor: 5.606
Authors: Anita N Bindraban; José Rolvink; Florine A Berger; Patricia M L A van den Bemt; Aaf F M Kuijper; Ruud T M van der Hoeven; Aukje K Mantel-Teeuwisse; Matthijs L Becker Journal: Int J Clin Pharm Date: 2018-07-26
Authors: Adrian Wong; Adam Wright; Diane L Seger; Mary G Amato; Julie M Fiskio; David Bates Journal: Appl Clin Inform Date: 2017-08-23 Impact factor: 2.342
Authors: Sunita Sharma; J Martijn Bos; Robert F Tarrell; Gyorgy J Simon; Bruce W Morlan; Michael J Ackerman; Pedro J Caraballo Journal: J Med Syst Date: 2017-09-02 Impact factor: 4.460